|
|
The accompanying notes are an integral part of these condensed consolidated financial statements.
| | | | | |
2025 Form 10-Q |  | 5 |
AbbVie Inc. and Subsidiaries
Notes to Condensed Consolidated Financial Statements (unaudited)
| Interest income | | () | | | () | | | () | | | () | |
| Interest expense, net | | $ | | | | $ | | | | $ | | | | $ | | |
| | $ | | | | Work-in-process | | | | | |
| Raw materials | | | | | |
| Inventories | $ | | | | $ | | |
| | | | | |
2025 Form 10-Q | | 6 |
| | $ | | | | Accumulated depreciation | () | | | () | |
| Property and equipment, net | $ | | | | $ | | |
Depreciation expense was $ million for the three months and $ million for the six months ended June 30, 2025 and $ million for the three months and $ million for the six months ended June 30, 2024.
| | $ | | | | $ | | | | $ | | | | Earnings allocated to participating securities | | | | | | | | | | | | |
| Earnings available to common shareholders | | $ | | | | $ | | | | $ | | | | $ | | |
| Weighted-average basic shares outstanding | | | | | | | | | | | | |
| Basic earnings per share attributable to AbbVie Inc. | | $ | | | | $ | | | | $ | | | | $ | | |
| | | | | | | | |
| Diluted EPS | | | | | | | | |
| Net earnings attributable to AbbVie Inc. | | $ | | | | $ | | | | $ | | | | $ | | |
| Earnings allocated to participating securities | | | | | | | | | | | | |
| Earnings available to common shareholders | | $ | | | | $ | | | | $ | | | | $ | | |
| Weighted-average shares of common stock outstanding | | | | | | | | | | | | |
| Effect of dilutive securities | | | | | | | | | | | | |
| Weighted-average diluted shares outstanding | | | | | | | | | | | | |
| Diluted earnings per share attributable to AbbVie Inc. | | $ | | | | $ | | | | $ | | | | $ | | |
Certain shares issuable under stock-based compensation plans were excluded from the computation of EPS because the effect would have been antidilutive. The number of common shares excluded was insignificant for all periods presented.
billion to acquire Capstan. The transaction is expected to close in 2025, subject to regulatory approvals and other customary closing conditions. | | | | | |
2025 Form 10-Q | | 7 |
million was comprised of a $ million upfront cash payment and $ million for the acquisition date fair value of contingent consideration liabilities, for which AbbVie may owe up to $ million in future payments upon achievement of certain development milestones. The transaction was accounted for as a business combination using the acquisition method of accounting. As of the acquisition date, AbbVie acquired $ million of intangible assets and resulted in the recognition of $ million of goodwill. Goodwill was calculated as the excess of the consideration transferred over the fair value of net assets recognized and represents the future economic benefits arising from other assets acquired that could not be individually identified and separately recognized, including expected synergies related to enhancement of AbbVie’s existing immunology discovery capabilities and development efforts. The goodwill is not deductible for tax purposes. Other assets acquired and liabilities assumed were insignificant.Acquisition of Cerevel Therapeutics Holdings, Inc.
On August 1, 2024, AbbVie completed its acquisition of Cerevel Therapeutics Holdings, Inc. (Cerevel Therapeutics). Cerevel Therapeutics is a clinical-stage biotechnology company focused on the discovery and development of differentiated therapies for neuroscience diseases. Cerevel Therapeutics neuroscience pipeline included multiple clinical-stage and preclinical candidates with the potential to treat several diseases including schizophrenia, Parkinson's disease and mood disorders. The total fair value of the consideration transferred to owners of Cerevel Therapeutics common stock was $ billion ($ billion, net of cash acquired). The acquisition of Cerevel Therapeutics was accounted for as a business combination using the acquisition method of accounting and the valuation of assets acquired and liabilities assumed was finalized during the three months ended March 31, 2025.
Acquisition of ImmunoGen, Inc.
On February 12, 2024, AbbVie completed its acquisition of ImmunoGen, Inc. (ImmunoGen). ImmunoGen is a commercial-stage biotechnology company focused on the discovery, development and commercialization of antibody-drug conjugates (ADC) for cancer patients. ImmunoGen's oncology portfolio included its flagship cancer therapy Elahere, a first-in-class ADC approved for platinum-resistant ovarian cancer, and a pipeline of promising next-generation ADC's targeting hematologic malignancies and solid tumors. The total fair value of the consideration transferred to owners of ImmunoGen common stock was $ billion ($ billion, net of cash acquired). The acquisition of ImmunoGen was accounted for as a business combination using the acquisition method of accounting and the valuation of assets acquired and liabilities assumed was finalized during the three months ended December 31, 2024.
Other Licensing & Acquisitions Activity
Cash outflows related to other acquisitions and investments totaled $ billion for the six months ended June 30, 2025 and $ billion for the six months ended June 30, 2024.
| | $ | | | | $ | | | | $ | | | | Development milestones | | | | | | | | | | | | |
| Acquired IPR&D and milestones | | $ | | | | $ | | | | $ | | | | $ | | |
| | | | | |
2025 Form 10-Q | | 8 |
million and receive an exclusive license to develop, manufacture and commercialize ISB-2001, a tri-specific T-cell engager for the treatment of multiple myeloma across North America, Europe, Japan, and Greater China. AbbVie could make additional payments of up to $ billion upon achievement of certain development, regulatory and commercial milestones and pay tiered royalties. The transaction is expected to close in 2025, subject to regulatory approvals and other customary closing conditions. ADARx Pharmaceuticals, Inc.
In May 2025, AbbVie entered into a license option agreement with ADARx Pharmaceuticals, Inc. (ADARx). Under the terms of the agreement, AbbVie received exclusive options to global license rights to develop and commercialize ADARx’s small interfering RNA (siRNA) therapeutics across multiple disease areas, including neuroscience, immunology and oncology. Under the terms of the agreement, AbbVie made an upfront payment of $ million which was recognized in acquired IPR&D and milestones expense in the condensed consolidated statement of earnings in the second quarter of 2025. AbbVie could make additional payments of up to $ million for option fees and option exercise payments, up to $ billion upon achievement of certain development, regulatory and commercial milestones and pay tiered royalties.
Gubra A/S
In April 2025, AbbVie completed its licensing agreement with Gubra A/S. Under the terms of the agreement, AbbVie received an exclusive global license to develop and commercialize GUB014295 (ABBV-295), a long-acting amylin analog for the treatment of obesity. Under the terms of the agreement, AbbVie made an upfront payment of $ million which was recognized in acquired IPR&D and milestones expense in the condensed consolidated statement of earnings in the second quarter of 2025. AbbVie could make additional payments of up to $ billion upon achievement of certain development, regulatory and commercial milestones and pay tiered royalties.
Celsius Therapeutics, Inc.
In June 2024, AbbVie acquired Celsius Therapeutics, Inc. (Celsius Therapeutics) including its lead pipeline asset CEL383. Celsius Therapeutics is a clinical-stage biotechnology company focused on the discovery and development of precision medicine in inflammatory bowel disease. The transaction was accounted as an asset acquisition as CEL383 represented substantially all of the fair value of the gross assets acquired. The upfront payment of $ million was recorded in acquired IPR&D and milestones expense in the condensed consolidated statement of earnings in the second quarter of 2024.
Note 5
million to AbbVie. The collaboration also includes a cost sharing arrangement for associated collaboration activities. Except in certain cases, Janssen is responsible for approximately % of collaboration development costs and AbbVie is responsible for the remaining % of collaboration development costs. | | | | | |
2025 Form 10-Q | | 9 |
| | $ | | | | $ | | | | $ | | | | International - AbbVie's share of profits (included in net revenues) | | | | | | | | | | | | |
| Global - AbbVie's share of other costs (included in respective line items) | | | | | | | | | | | | |
AbbVie’s receivable from Janssen, included in accounts receivable, net, was $ million at June 30, 2025 and $ million at December 31, 2024. AbbVie’s payable to Janssen, included in accounts payable and accrued liabilities, was $ million at June 30, 2025 and $ million at December 31, 2024.
Collaboration with Genentech, Inc.
AbbVie and Genentech, Inc. (Genentech), a member of the Roche Group, are parties to a collaboration and license agreement executed in 2007 to jointly research, develop and commercialize human therapeutic products containing BCL-2 inhibitors and certain other compound inhibitors which includes Venclexta, a BCL-2 inhibitor used to treat certain hematological malignancies. AbbVie shares equally with Genentech all pre-tax profits and losses from the development and commercialization of Venclexta in the United States. AbbVie pays royalties on Venclexta net revenues outside the United States.
AbbVie manufactures and distributes Venclexta globally and is the principal in the end-customer product sales. Sales of Venclexta are included in AbbVie’s net revenues. Genentech’s share of United States profits is included in AbbVie’s cost of products sold. AbbVie records sales and marketing costs associated with the United States collaboration as part of selling, general and administrative (SG&A) expenses and global development costs as part of research and development (R&D) expenses, net of Genentech’s share. Royalties paid for Venclexta revenues outside the United States are also included in AbbVie’s cost of products sold.
| | $ | | | | $ | | | | $ | | | | AbbVie's share of sales and marketing costs from U.S. collaboration (included in SG&A) | | | | | | | | | | | | |
| AbbVie's share of development costs (included in R&D) | | | | | | | | | | | | |
| | | | | |
2025 Form 10-Q | | 10 |
| Additions(a) | | |
| Foreign currency translation adjustments | | |
| Balance as of June 30, 2025 | $ | | |
(a) Goodwill additions related to the acquisition of Nimble (see Note 4).
The company performs its annual goodwill impairment assessment in the third quarter, or earlier if impairment indicators exist. As of June 30, 2025, there were accumulated goodwill impairment losses.
Intangible Assets, Net
| | $ | () | | | $ | | | | $ | | | | $ | () | | | $ | | | | License agreements | | | | () | | | | | | | | | () | | | | |
| Total definite-lived intangible assets | | | | () | | | | | | | | | () | | | | |
| Indefinite-lived intangible assets | | | | — | | | | | | | | | — | | | | |
| Total intangible assets, net | $ | | | | $ | () | | | $ | | | | $ | | | | $ | () | | | $ | | |
Definite-Lived Intangible Assets
Amortization expense was $ billion for the three months and $ billion for the six months ended June 30, 2025 and $ billion for the three months and $ billion for the six months ended June 30, 2024. Amortization expense was included in cost of products sold in the condensed consolidated statements of earnings.
Indefinite-Lived Intangible Assets
Indefinite-lived intangible assets represent acquired IPR&D associated with products that have not yet received regulatory approval. The company performs its annual impairment assessment of indefinite-lived intangible assets in the third quarter, or earlier if impairment indicators exist.
| | | | | |
2025 Form 10-Q | | 11 |
million for the three months and $ million for the six months ended June 30, 2025 and $ million for the three months and $ million for the six months ended June 30, 2024. These charges are recognized in cost of products sold, R&D expense and SG&A expense in the condensed consolidated statements of earnings based on the classification of the affected employees or the related operations. | | Restructuring charges | | |
| Payments and other adjustments | () | |
| Accrued balance as of June 30, 2025 | $ | | |
billion at June 30, 2025 and $ billion at December 31, 2024, are designated as cash flow hedges and are recorded at fair value. The durations of these forward exchange contracts were generally less than months. Accumulated gains and losses as of June 30, 2025 are reclassified from accumulated other comprehensive income (loss) (AOCI) and included in cost of products sold at the time the products are sold, generally not exceeding from the date of settlement.The company also enters into foreign currency forward exchange contracts to manage its exposure to foreign currency denominated trade payables and receivables and intercompany loans. These contracts are not designated as hedges and are recorded at fair value. Resulting gains or losses are reflected in net foreign exchange loss in the condensed consolidated statements of earnings and are generally offset by losses or gains on the foreign currency exposure being managed. These contracts had notional amounts totaling $ billion at June 30, 2025 and $ billion at December 31, 2024.
The company also uses foreign currency forward exchange contracts or foreign currency denominated debt to hedge its net investments in certain foreign subsidiaries and affiliates. The company had an aggregate principal amount of senior Euro notes designated as net investment hedges of € billion at June 30, 2025 and December 31, 2024. In addition, the company had foreign currency forward exchange contracts designated as net investment hedges with notional amounts totaling € billion, SEK billion, CAD million and CHF million at June 30, 2025 and € billion, SEK billion, CAD million and CHF million at December 31, 2024. The company uses the spot method of assessing hedge effectiveness for derivative instruments designated as net investment hedges. Realized and unrealized gains and losses from these hedges are included in AOCI and the initial fair value of hedge components excluded from the assessment of effectiveness is recognized in interest expense, net over the life of the hedging instrument.
The company is a party to interest rate swap contracts designated as fair value hedges with notional amounts totaling $ billion at June 30, 2025 and December 31, 2024. The effect of the hedge contracts is to change a fixed-rate interest obligation to a floating rate for that portion of the debt. AbbVie records the contracts at fair value and adjusts the carrying amount of the fixed-rate debt by an offsetting amount.
amounts are excluded from the assessment of effectiveness for cash flow hedges or fair value hedges.
| | | | | |
2025 Form 10-Q | | 12 |
| $ | | | | Accounts payable and accrued liabilities | $ | | | $ | | | | Designated as cash flow hedges | Other assets | | | | | | Other long-term liabilities | | | | |
| Designated as net investment hedges | Prepaid expenses and other | | | | | | Accounts payable and accrued liabilities | | | | |
| Designated as net investment hedges | Other assets | | | | | | Other long-term liabilities | | | | |
| Not designated as hedges | Prepaid expenses and other | | | | | | Accounts payable and accrued liabilities | | | | |
| | | |
| | | |
| Interest rate swap contracts | | | | | | | |
| | | |
| Designated as fair value hedges | Other assets | | | | | | Other long-term liabilities | | | | |
| Total derivatives | | $ | | | $ | | | | | $ | | | $ | | |
While certain derivatives are subject to netting arrangements with the company’s counterparties, the company does not offset derivative assets and liabilities within the condensed consolidated balance sheets.
) | | $ | | | | $ | () | | | $ | | | | Designated as net investment hedges | | () | | | | | | () | | | | |
| | | | | Assuming market rates remain constant through contract maturities, the company expects to reclassify pre-tax losses of $ million into cost of products sold for foreign currency cash flow hedges and pre-tax gains of $ million into interest expense, net for other cash flow hedges during the next 12 months.
Related to AbbVie’s non-derivative, foreign currency denominated debt designated as net investment hedges, the company recognized in other comprehensive income (loss) pre-tax losses of $ million for the three months and $ million for the six months ended June 30, 2025 and pre-tax gains of $ million for the three months and $ million for the six months ended June 30, 2024.
| | $ | | | | $ | | | | $ | | |
| Designated as net investment hedges | Interest expense, net | | | | | | | | | | | | |
| Not designated as hedges | Net foreign exchange loss | | () | | | | | | () | | | | |
| Interest rate swap contracts | | | | | | | | | |
| Designated as fair value hedges | Interest expense, net | | | | | | | | | | | () | |
| Debt designated as hedged item in fair value hedges | Interest expense, net | | () | | | () | | | () | | | | |
Other | Interest expense, net | | | | | | | | | | | | |
| | | | | |
2025 Form 10-Q | | 13 |
| | $ | | | | $ | | | | $ | | | | Money market funds and time deposits | | | | | | | | | | | |
| Debt securities | | | | | | | | | | | |
| Equity securities | | | | | | | | | | | |
| Interest rate swap contracts | | | | | | | | | | | |
| Foreign currency contracts | | | | | | | | | | | |
| | | |
| Total assets | $ | | | | $ | | | | $ | | | | $ | | |
| Liabilities | | | | | | | |
| Interest rate swap contracts | $ | | | | $ | | | | $ | | | | $ | | |
| | | |
| Foreign currency contracts | | | | | | | | | | | |
| Financing liability | | | | | | | | | | | |
| Contingent consideration | | | | | | | | | | | |
| Total liabilities | $ | | | | $ | | | | $ | | | | $ | | |
| | | | | |
2025 Form 10-Q | | 14 |
| | $ | | | | $ | | | | $ | | | | Money market funds and time deposits | | | | | | | | | | | |
| Debt securities | | | | | | | | | | | |
| Equity securities | | | | | | | | | | | |
| Foreign currency contracts | | | | | | | | | | | |
| Total assets | $ | | | | $ | | | | $ | | | | $ | | |
| Liabilities | | | | | | | |
| Interest rate swap contracts | $ | | | | $ | | | | $ | | | | $ | | |
| Foreign currency contracts | | | | | | | | | | | |
| Financing liability | | | | | | | | | | | |
| Contingent consideration | | | | | | | | | | | |
| Total liabilities | $ | | | | $ | | | | $ | | | | $ | | |
Money market funds and time deposits are valued using relevant observable market inputs including quoted prices for similar assets and interest rate curves. Equity securities primarily consist of investments for which the fair values were determined by using the published market prices per unit multiplied by the number of units held, without consideration of transaction costs. The derivatives entered into by the company were valued using observable market inputs including published interest rate curves and both forward and spot prices for foreign currencies.
The financing liability is related to financing arrangements which the company elected to account for in accordance with the fair value option, as permitted under ASC 825 Financial Instruments. The fair value measurement of the financing liability was determined based on significant unobservable inputs. Potential payments are estimated by applying a probability-weighted expected payment model, which are then discounted to present value. Changes to the fair value of the financing liability can result from changes to one or a number of inputs, including discount rates, estimated probabilities and timing of achieving milestones and estimated amounts of future sales. The change in fair value recognized in net earnings is recorded in other expense, net in the condensed consolidated statements of earnings and the change in fair value attributable to instrument-specific credit risk is recognized in other comprehensive income (loss). Changes in fair value recognized in other expense, net and in other comprehensive income (loss) for the three and six months ended June 30, 2025 were insignificant.
The fair value measurements of the contingent consideration liabilities were determined based on significant unobservable inputs, including the discount rate, estimated probabilities and timing of achieving specified development, regulatory and commercial milestones and the estimated amount of future sales of the acquired products. The potential contingent consideration payments are estimated by applying a probability-weighted expected payment model for contingent milestone payments and a Monte Carlo simulation model for contingent royalty payments, which are then discounted to present value. Changes to the fair value of the contingent consideration liabilities can result from changes to one or a number of inputs, including discount rates, the probabilities of achieving the milestones, the time required to achieve the milestones and estimated future sales. Significant judgment is employed in determining the appropriateness of certain of these inputs. Changes to the inputs described above could have a material impact on the company's financial position and results of operations in any given period.
| | | | | |
2025 Form 10-Q | | 15 |
% - %% | | % - % | % | Probability of payment for royalties by indication | % | % | | % | % |
| |
| Projected year of payments | - |
| | - |
|
There have been transfers of assets or liabilities into or out of Level 3 of the fair value hierarchy. | | $ | | | Additions(a) | | | | | | |
| Change in fair value recognized in net earnings | | | | | | |
| Payments | | () | | | () | |
| Ending balance | | $ | | | | $ | | |
The change in fair value recognized in net earnings is recorded in other expense, net in the condensed consolidated statements of earnings.
Certain financial instruments are carried at historical cost or some basis other than fair value.
| $ | | | | $ | | | | $ | | | | $ | | | | Current portion of long-term debt and finance lease obligations, excluding fair value hedges | | | | | | | | | | | | | |
Long-term debt and finance lease obligations, excluding fair value hedges and financing liability | | | | | | | | | | | | | |
| Total liabilities | $ | | | $ | | | | $ | | | | $ | | | | $ | | |
| | | | | |
2025 Form 10-Q | | 16 |
| | $ | () | | Other comprehensive loss for the six months ended June 30, 2024 included foreign currency translation adjustments totaling a loss of $ million principally due to the impact of the weakening of the Euro on the translation of the company’s Euro-denominated assets and the offsetting impact of net investment hedging activities totaling a gain of $ million.
) | | $ | () | | | $ | () | | | $ | () | | | Tax expense | | | | | | | | | | | |
| Total reclassifications, net of tax | $ | () | | | $ | () | | | $ | () | | | $ | () | |
| Pension and post-employment benefits | | | | | | | |
Amortization of actuarial losses and other(b) | $ | | | | $ | | | | $ | | | | $ | | |
| Tax benefit | () | | | () | | | () | | | () | |
| Total reclassifications, net of tax | $ | | | | $ | | | | $ | | | | $ | | |
| Cash flow hedging activities | | | | | | | |
Gains on foreign currency forward exchange contracts(c) | $ | () | | | $ | () | | | $ | () | | | $ | () | |
Other(a) | () | | | () | | | () | | | () | |
| | | |
| | | |
Tax expense | | | | | | | | | | | |
| Total reclassifications, net of tax | $ | () | | | $ | () | | | $ | () | | | $ | () | |
.
| | | | | |
2025 Form 10-Q | | 21 |
Note 11 % for the three months and % for the six months ended June 30, 2025 compared to % for the three months and % for the six months ended June 30, 2024. The effective tax rate in each period differed from the U.S. statutory tax rate of % principally due to the impact of foreign operations which reflects the impact of lower income tax rates in locations outside the United States, changes in fair value of contingent consideration and business development activities. The increase in the effective tax rate for the three months and six months ended June 30, 2025 over the prior year was primarily due to changes in fair value of contingent consideration offset by changes in jurisdictional mix of earnings and business development activities.
Note 12 billion as of June 30, 2025 and $ billion as of December 31, 2024. For litigation matters discussed below for which a loss is probable or reasonably possible, the company is unable to estimate the possible loss or range of loss, if any, beyond the amounts accrued. Initiation of new legal proceedings or a change in the status of existing proceedings may result in a change in the estimated loss accrued by AbbVie. While it is not feasible to predict the outcome of all proceedings and exposures with certainty, management believes that their ultimate disposition should not have a material adverse effect on AbbVie’s consolidated financial position, results of operations or cash flows.
individual plaintiff lawsuits and a certified class action by Niaspan direct purchasers. The cases are pending in the United States District Court for the Eastern District of Pennsylvania for coordinated or consolidated pre-trial proceedings under the federal multi-district litigation (MDL) Rules as In re: Niaspan Antitrust Litigation, MDL No. 2460. In October 2016, the Orange County, California District Attorney’s Office filed a lawsuit on behalf of the State of California regarding the Niaspan patent litigation settlement in Orange County Superior Court, asserting a claim under the unfair competition provision of the California Business and Professions Code seeking injunctive relief, restitution, civil penalties and attorneys’ fees.Government Proceedings
Lawsuits are pending against Allergan and several other manufacturers generally alleging that they improperly promoted and sold prescription opioid products. Approximately lawsuits are pending against Allergan in federal and state courts. Most of the federal court lawsuits are consolidated for pre-trial purposes in the United States District Court for the Northern District of Ohio under the MDL rules as In re: National Prescription Opiate Litigation, MDL No. 2804. Approximately of the lawsuits are pending in various state courts. The plaintiffs in these lawsuits, which include states, counties, cities, other municipal entities, Native American tribes, union trust funds and other third-party payors, private hospitals and personal injury claimants, generally seek compensatory and punitive damages. Of these approximately lawsuits, approximately of them are brought by states, counties, cities, and other municipal entities, approximately of which are in the process of being dismissed pursuant to the previously announced settlement.
| | | | | |
2025 Form 10-Q | | 22 |
million income tax benefit recorded in 2014 related to a payment made to a third party for the termination of a proposed business combination. In June 2025, the United States Tax Court granted AbbVie’s motion for summary judgment and denied the Commissioner of Internal Revenue’s cross-motion for summary judgment. The United States Tax Court ordered and decided that there is no deficiency in income tax due from AbbVie for the tax year 2014. Shareholder and Securities Litigation
In May 2024, a putative class action lawsuit, Reese v. AbbVie Inc., was filed in Delaware Chancery Court challenging the lawfulness of Section 2.13(D)(iv) in the Second Amended and Restated By-laws of AbbVie Inc. As noted in its Form 8-K filed on September 6, 2024, AbbVie believed this provision was lawful but no longer had any practical value. Accordingly, AbbVie did not believe defending this provision was the best use of Company resources. AbbVie therefore amended its by-laws to, among other things, delete section 2.13(D)(iv). As a result of this amendment, plaintiff agreed that his claims were moot. In September 2024, the court granted an Order Voluntarily Dismissing the Action as Moot and Retaining Jurisdiction to Determine Plaintiff's Counsel’s Application for an Award of Attorneys’ Fees and Reimbursement of Expenses. To avoid the time and expense of continued litigation and without any admissions, the parties agreed to resolve plaintiff’s counsel fee application with a payment of $ thousand to plaintiff’s counsel. In July 2025, the court entered a stipulation and order providing that the case will be closed. In entering that order, the court was not asked to review, and did not pass judgment on, the payment of the attorneys’ fees and expenses or their reasonableness.
In October 2018, a federal securities lawsuit, Holwill v. AbbVie Inc., et al., was filed in the United States District Court for the Northern District of Illinois against AbbVie, its former chief executive officer and former chief financial officer, alleging that reasons stated for Humira sales growth in financial filings between 2013 and 2018 were misleading because they omitted alleged misconduct in connection with Humira patient and reimbursement support services and other services and items of value that allegedly induced Humira prescriptions. In September 2021, the court granted plaintiffs' motion to certify a class. In July 2025, the court granted AbbVie and the individual defendants’ motion for summary judgement.
Product Liability and General Litigation
In April 2023, a putative class action lawsuit, Camargo v. AbbVie Inc., was filed in the United States District Court for the Northern District of Illinois on behalf of Humira patients who paid for Humira based on its list price or who, after losing insurance coverage, discontinued Humira because they could not pay based on its list price, alleging that Humira’s list price is excessive in violation of multiple states’ unfair and deceptive trade practices statutes. The plaintiff generally seeks monetary damages, injunctive relief, and attorneys’ fees.
Lawsuits are pending against various Allergan entities in the United States and other countries including Australia, Brazil, Canada, South Korea, and the Netherlands, in which plaintiffs generally allege that they developed, or may develop, breast implant-associated anaplastic large cell lymphoma (ALCL) or other injuries from Allergan’s Biocell® textured breast implants, which were voluntarily withdrawn from worldwide markets in 2019. Approximately ALCL lawsuits and other lawsuits are coordinated for pre-trial purposes in the United States District Court for the District of New Jersey under the MDL rules as In re: Allergan Biocell Textured Breast Implant Product Liability Litigation, MDL No. 2921. Approximately ALCL lawsuits and other lawsuits are pending in various state courts. Approximately ALCL and other lawsuits are pending in other countries. Plaintiffs generally seek monetary damages, medical monitoring, and attorneys’ fees.
In January 2025, a putative class action lawsuit, Sheet Metal Workers’ Health Plan of Southern California, Arizona, and Nevada v. AbbVie Inc., was filed in the United States District Court for the Northern District of Illinois on behalf of third-party payors of Humira, alleging that AbbVie’s rebating practices are impairing biosimilar competition with Humira in violation of federal and state antitrust laws. The plaintiff generally seeks monetary damages, injunctive relief and attorneys' fees.
Intellectual Property Litigation
AbbVie Inc. is seeking to enforce patent rights relating to upadacitinib (a drug sold under the trademark Rinvoq). Litigation was filed in the United States District Court for the District of Delaware in November 2023 against Hetero USA, Inc., Hetero Labs Limited, Hetero Labs Limited Unit-V, Aurobindo Pharma USA, Inc. and Aurobindo Pharma Ltd. AbbVie alleges defendants’ proposed generic upadacitinib products infringe certain patents and seeks declaratory and injunctive relief.
AbbVie Inc. is seeking to enforce patent rights related to ubrogepant (a drug sold under the trademark Ubrelvy). Litigation was filed in the United States District Court for the District of New Jersey in March 2024 against Aurobindo Pharma U.S.A., Inc., Aurobindo Pharma Limited, and Apitoria Pharma Private Limited; Zydus Pharmaceuticals (USA) Inc. and Zydus Lifesciences Limited; MSN Pharmaceuticals Inc., MSN Laboratories Private Limited, and MSN Life Sciences Private Limited; and Hetero USA Inc., Hetero Labs
| | | | | |
2025 Form 10-Q | | 23 |
| | | | | |
2025 Form 10-Q | | 24 |
| | $ | | | | $ | | | | $ | | | | International | | | | | | | | | | | |
| Total | $ | | | | $ | | | | $ | | | | $ | | |
| Rinvoq | United States | $ | | | | $ | | | | $ | | | | $ | | |
| International | | | | | | | | | | | |
| Total | $ | | | | $ | | | | $ | | | | $ | | |
| Humira | United States | $ | | | | $ | | | | $ | | | | $ | | |
| International | | | | | | | | | | | |
| Total | $ | | | | $ | | | | $ | | | | $ | | |
| Neuroscience | | | | | | | |
| Vraylar | United States | $ | | | | $ | | | | $ | | | | $ | | |
| International | | | | | | | | | | | |
| Total | $ | | | | $ | | | | $ | | | | $ | | |
| Botox Therapeutic | United States | $ | | | | $ | | | | $ | | | | $ | | |
| International | | | | | | | | | | | |
| Total | $ | | | | $ | | | | $ | | | | $ | | |
| Ubrelvy | United States | $ | | | | $ | | | | $ | | | | $ | | |
| International | | | | | | | | | | | |
| Total | $ | | | | $ | | | | $ | | | | $ | | |
| Qulipta | United States | $ | | | | $ | | | | $ | | | | $ | | |
| International | | | | | | | | | | | |
| Total | $ | | | | $ | | | | $ | | | | $ | | |
| Vyalev | United States | $ | | | | $ | | | | $ | | | | $ | | |
| International | | | | | | | | | | | |
| Total | $ | | | | $ | | | | $ | | | | $ | | |
| Duodopa | United States | $ | | | | $ | | | | $ | | | | $ | | |
| International | | | | | | | | | | | |
| Total | $ | | | | $ | | | | $ | | | | $ | | |
| Other Neuroscience | United States | $ | | | | $ | | | | $ | | | | $ | | |
| International | | | | | | | | | | | |
| Total | $ | | | | $ | | | | $ | | | | $ | | |
| | | | | |
2025 Form 10-Q | | 25 |
| | $ | | | | $ | | | | $ | | | | Collaboration revenues | | | | | | | | | | | |
| Total | $ | | | | $ | | | | $ | | | | $ | | |
| Venclexta | United States | $ | | | | $ | | | | $ | | | | $ | | |
| International | | | | | | | | | | | |
| Total | $ | | | | $ | | | | $ | | | | $ | | |
| Elahere | United States | $ | | | | $ | | | | $ | | | | $ | | |
| International | | | | | | | | | | | |
| Total | $ | | | | $ | | | | $ | | | | $ | | |
| Epkinly | Collaboration revenues | $ | | | | $ | | | | $ | | | | $ | | |
| International | | | | | | | | | | | |
| Total | $ | | | | $ | | | | $ | | | | $ | | |
| Other Oncology | United States | $ | | | | $ | | | | $ | | | | $ | | |
| Aesthetics | | | | | | | |
| Botox Cosmetic | United States | $ | | | | $ | | | | $ | | | | $ | | |
| International | | | | | | | | | | | |
| Total | $ | | | | $ | | | | $ | | | | $ | | |
| Juvederm Collection | United States | $ | | | | $ | | | | $ | | | | $ | | |
| International | | | | | | | | | | | |
| Total | $ | | | | $ | | | | $ | | | | $ | | |
| Other Aesthetics | United States | $ | | | | $ | | | | $ | | | | $ | | |
| International | | | | | | | | | | | |
| Total | $ | | | | $ | | | | $ | | | | $ | | |
| Eye Care | | | | | | | |
| Ozurdex | United States | $ | | | | $ | | | | $ | | | | $ | | |
| International | | | | | | | | | | | |
| Total | $ | | | | $ | | | | $ | | | | $ | | |
| Lumigan/Ganfort | United States | $ | | | | $ | | | | $ | | | | $ | | |
| International | | | | | | | | | | | |
| Total | $ | | | | $ | | | | $ | | | | $ | | |
| Alphagan/Combigan | United States | $ | | | | $ | | | | $ | | | | $ | | |
| International | | | | | | | | | | | |
| Total | $ | | | | $ | | | | $ | | | | $ | | |
| Other Eye Care | United States | $ | | | | $ | | | | $ | | | | $ | | |
| International | | | | | | | | | | | |
| Total | $ | | | | $ | | | | $ | | | | $ | | |
| Other Key Products | | | | | | | |
| Mavyret | United States | $ | | | | $ | | | | $ | | | | $ | | |
| International | | | | | | | | | | | |
| Total | $ | | | | $ | | | | $ | | | | $ | | |
| Creon | United States | $ | | | | $ | | | | $ | | | | $ | | |
| Linzess/Constella | United States | $ | | | | $ | | | | $ | | | | $ | | |
| International | | | | | | | | | | | |
| Total | $ | | | | $ | | | | $ | | | | $ | | |
| All other | | $ | | | | $ | | | | $ | | | | $ | | |
| Total net revenues | $ | | | | $ | | | | $ | | | | $ | | |
| | | | | |
2025 Form 10-Q | | 26 |
ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS The following is a discussion and analysis of the financial condition of AbbVie Inc. (AbbVie or the company) as of June 30, 2025 and December 31, 2024 and the results of operations for the three and six months ended June 30, 2025 and 2024. This commentary should be read in conjunction with the Condensed Consolidated Financial Statements and accompanying notes appearing in Item 1, “Financial Statements and Supplementary Data.”
EXECUTIVE OVERVIEW
Company Overview
AbbVie is a global, diversified research-based biopharmaceutical company positioned for success with a comprehensive product portfolio that has leadership positions across immunology, neuroscience, oncology, aesthetics and eye care. AbbVie uses its expertise, dedicated people and unique approach to innovation to develop and market advanced therapies that address some of the world’s most complex and serious diseases.
On February 13, 2025, the board of directors of AbbVie unanimously elected Chief Executive Officer (CEO) Robert A. Michael to succeed Richard A. Gonzalez as Chairman of the board of directors, effective July 1, 2025, at which time Mr. Gonzalez retired from the board.
AbbVie's products are generally sold worldwide directly to wholesalers, distributors, government agencies, health care facilities, specialty pharmacies and independent retailers from AbbVie-owned distribution centers and public warehouses. Certain products (including aesthetic products and devices) are also sold directly to physicians and other licensed healthcare providers. In the United States, AbbVie distributes pharmaceutical products principally through independent wholesale distributors, with some sales directly to retailers, pharmacies, patients or other customers. Outside the United States, AbbVie sells products primarily to wholesalers or through distributors, and depending on the market works through largely centralized national payers system to agree on reimbursement terms. Certain products are co-marketed or co-promoted with other companies. AbbVie operates as a single global business segment and has approximately 55,000 employees.
2025 Strategic Objectives
AbbVie's mission is to discover and develop innovative medicines and products that solve serious health issues today and address the medical challenges of tomorrow while achieving top-tier financial performance through outstanding execution. AbbVie intends to execute its strategy and advance its mission in a number of ways, including: (i) maximizing the benefits of a diversified revenue base with multiple long-term growth drivers; (ii) leveraging AbbVie's commercial strength and international infrastructure across therapeutic areas and ensuring strong commercial execution of new product launches; (iii) continuing to invest in and expand its pipeline in support of opportunities in immunology, neuroscience, oncology, aesthetics and eye care as well as continued investment in key on-market products; (iv) generating substantial operating cash flows to support investment in innovative research and development, and return cash to shareholders via a strong and growing dividend while also continuing to repay debt. In addition, AbbVie anticipates several regulatory submissions and data readouts from key clinical trials in the next 12 months.
Financial Results
The company’s financial performance for the six months ended June 30, 2025 included delivering worldwide net revenues of $28.8 billion, operating earnings of $8.6 billion, diluted earnings per share of $1.24 and cash flows from operations of $6.8 billion. Worldwide net revenues increased 7% on a reported basis and 8% on a constant currency basis.
Financial results for the six months ended June 30, 2025 also included the following costs: (i) $3.7 billion related to the amortization of intangible assets; and (ii) $4.3 billion for the change in fair value of contingent consideration liabilities. Additionally, financial results reflected continued funding to support all stages of AbbVie’s pipeline assets and continued investment in AbbVie’s on-market brands.
| | | | | |
2025 Form 10-Q | | 27 |
Recent Events
AbbVie’s business may be impacted by risks associated with global macroeconomic conditions, including international trade disruptions and disputes as well as trade protection measures. For example, the United States government has recently imposed broad-based tariffs targeting specified countries. While the impact of these tariffs on AbbVie’s business and results of operations to date has not been material, the United States government may in the future pause, reimpose or increase tariffs and foreign governments have and, in the future, may impose retaliatory trade protection measures. Any new or additional tariffs, particularly those targeting the pharmaceuticals industry, may increase uncertainties and associated risks and could adversely impact AbbVie’s business and results of operations.
AbbVie is also subject to public and legislative pressure with respect to pharmaceutical pricing. In the United States, Executive Order 14297, issued on May 12, 2025, directs the Secretary of Health and Human Services (HHS) to pursue most-favored-nation (MFN) pricing, defined as the lowest price in any Organization for Economic Co-operation and Development country with a gross domestic product per capita of at least 60% of that of the United States. The order directs HHS to implement policies mandating MFN pricing along with other regulatory actions if substantial progress toward voluntary compliance is not achieved. AbbVie continues to evaluate the potential impact of this executive order, and any new or additional legislation, regulations or executive orders related to pharmaceutical pricing may increase uncertainties and associated risks and could adversely impact AbbVie’s business and results of operations.
On July 4, 2025, the United States government signed into law the One Big Beautiful Bill Act of 2025 (2025 Act). Included within the 2025 Act are certain new tax provisions, limitations and modifications to existing tax provisions that were previously enacted under the Tax Cuts and Jobs Act of 2017, including rules related to the taxation of income earned outside of the United States and the tax treatment of domestic performed research and development costs. In addition, the legislation contains various effective dates and transition elections. The 2025 Act also includes certain new health care provisions related to the orphan drug exclusion of the Inflation Reduction Act of 2022, and Medicaid, which have various effective dates. AbbVie is currently evaluating the impact of the 2025 Act on its consolidated financial statements.
Research and Development
Research and innovation are the cornerstones of AbbVie’s business as a global biopharmaceutical company. AbbVie’s long-term success depends to a great extent on its ability to continue to discover and develop innovative products and acquire or collaborate on compounds currently in development by other biotechnology or pharmaceutical companies.
AbbVie’s pipeline currently includes approximately 90 compounds, devices or indications in development individually or under collaboration or license agreements. Of these programs, approximately 50 are in mid- and late-stage development. The company’s pipeline is focused on such important specialties as immunology, neuroscience, oncology, aesthetics and eye care. AbbVie’s recently announced partnership with Gubra marks the company’s entrance into the obesity field, a therapeutic area with significant unmet need.
The following sections summarize transitions of significant programs from mid-stage development to late-stage development as well as developments in significant late-stage and registration programs. AbbVie expects multiple mid-stage programs to transition into late-stage programs in the next 12 months.
Significant Programs and Developments
Immunology
Rinvoq
•In April 2025, AbbVie announced that the European Commission (EC) granted marketing authorization to Rinvoq for the treatment of giant cell arteritis (GCA) in adult patients.
•In April 2025, AbbVie announced that the U.S. Food and Drug Administration (FDA) approved Rinvoq for the treatment of GCA in adult patients.
•In July 2025, AbbVie announced positive topline results from Study 2 of its Phase 3 UP-AA trial for Rinvoq as a monotherapy in adults and adolescents with severe alopecia areata.
| | | | | |
2025 Form 10-Q | | 28 |
Neuroscience
Qulipta
•In February 2025, AbbVie initiated a Phase 3 clinical trial to evaluate Qulipta for the preventive treatment of menstrual migraine.
•In June 2025, AbbVie announced positive topline results from its Phase 3 TEMPLE head-to-head study evaluating the tolerability, safety and efficacy of Qulipta compared to the highest tolerated dose of topiramate in adult patients with a history of four or more migraine days per month.
Oncology
Emrelis
•In May 2025, AbbVie announced that the U.S. FDA granted accelerated approval for Emrelis (telisotuzumab vedotin-tllv) for the treatment of adult patients with locally advanced or metastatic, non-squamous non-small cell lung cancer with high c-Met protein overexpression who have received a prior systemic therapy.
Venclexta
•In June 2025, AbbVie announced that the global Phase 3 VERONA trial evaluating Venclexta in combination with azacitidine in the treatment of newly diagnosed higher-risk myelodysplastic syndrome did not meet the primary endpoint of overall survival. No new safety signals were observed.
•In July 2025, AbbVie announced the submission of a supplemental New Drug Application (sNDA) to the U.S. FDA for the fixed-duration, all oral combination regimen of Venclexta and acalabrutinib in previously untreated patients with chronic lymphocytic leukemia (CLL). The submission is supported by positive results from the Phase 3 AMPLIFY trial which demonstrated that the combination regimen improved progression-free survival compared to standard chemoimmunotherapy in previously untreated patients with CLL.
Epkinly
•In May 2025, Genmab A/S (Genmab) announced positive topline results from the Phase 3 trial evaluating Epkinly plus rituximab and lenalidomide versus rituximab and lenalidomide alone in adult patients with relapsed or refractory follicular lymphoma.
Aesthetics
TrenibotE
•In April 2025, AbbVie announced that it submitted a Biologics License Application (BLA) to the U.S. FDA for approval of trenibotulinumtoxinE (TrenibotE) for the treatment of moderate to severe glabellar lines. TrenibotE is a first-in-class botulinum neurotoxin serotype E characterized by a rapid onset of action as early as 8 hours after administration and short duration of effect of 2-3 weeks. If approved, TrenibotE will be the first neurotoxin of its kind available to patients.
Juvederm Collection
•In June 2025, AbbVie announced that the U.S. FDA accepted for review the supplemental premarket approval application for Skinvive by Juvederm to reduce neck lines for the improvement of neck appearance.
Other
Emblaveo
•In February 2025, AbbVie announced that the U.S. FDA approved Emblaveo (aztreonam and avibactam), as the first fixed-dose, intravenous, monobactam/β-lactamase inhibitor combination antibiotic to treat complicated intra-abdominal infections, including those caused by Gram-negative bacteria.
Mavyret
•In June 2025, AbbVie announced that the U.S FDA approved a label expansion for Mavyret, an oral pangenotypic direct acting antiviral therapy. It is now approved for the treatment of adults and pediatric patients three years and older with acute or chronic hepatitis C virus infection immediately at the time of diagnosis.
For a more comprehensive discussion of AbbVie’s products and pipeline, see the company’s Annual Report on Form 10-K for the year ended December 31, 2024.
| | | | | |
2025 Form 10-Q | | 29 |
RESULTS OF OPERATIONS
Net Revenues
The comparisons presented at constant currency rates reflect comparative local currency net revenues at the prior year’s foreign exchange rates. This measure provides information on the change in net revenues assuming that foreign currency exchange rates had not changed between the prior and current periods. AbbVie believes that the non-GAAP measure of change in net revenues at constant currency rates, when used in conjunction with the GAAP measure of change in net revenues at actual currency rates, may provide a more complete understanding of the company’s operations and can facilitate analysis of the company’s results of operations, particularly in evaluating performance from one period to another.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | Three months ended
June 30, | | Percent change | | Six months ended
June 30, | | Percent change |
| | | At actual
currency rates | | At constant
currency rates | | | At actual
currency rates | | At constant
currency rates |
(dollars in millions) | | 2025 | | 2024 | | | 2025 | | 2024 | |
United States | | $ | 11,762 | | | $ | 11,106 | | | 5.9 | % | | 5.9 | % | | $ | 21,741 | | | $ | 20,147 | | | 7.9 | % | | 7.9 | % |
International | | 3,661 | | | 3,356 | | | 9.1 | % | | 8.4 | % | | 7,025 | | | 6,625 | | | 6.0 | % | | 8.3 | % |
Net revenues | | $ | 15,423 | | | $ | 14,462 | | | 6.6 | % | | 6.5 | % | | $ | 28,766 | | | $ | 26,772 | | | 7.4 | % | | 8.0 | % |
| | | | | |
2025 Form 10-Q | | 30 |
The following table details AbbVie’s worldwide net revenues: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | Three months ended
June 30, | | Percent change | | Six months ended
June 30, | | Percent change |
| | | | At actual
currency rates | | At constant
currency rates | | | At actual
currency rates | | At constant
currency rates |
(dollars in millions) | | 2025 | | 2024 | | | 2025 | | 2024 | |
| Immunology | | | | | | | | | | | | | | | | |
| Skyrizi | United States | | $ | 3,843 | | | $ | 2,340 | | | 64.3 | % | | 64.3 | % | | $ | 6,762 | | | $ | 3,996 | | | 69.2 | % | | 69.2 | % |
| International | | 580 | | | 387 | | | 49.7 | % | | 47.2 | % | | 1,086 | | | 739 | | | 46.9 | % | | 49.6 | % |
| Total | | $ | 4,423 | | | $ | 2,727 | | | 62.2 | % | | 61.8 | % | | $ | 7,848 | | | $ | 4,735 | | | 65.8 | % | | 66.2 | % |
| Rinvoq | United States | | $ | 1,452 | | | $ | 1,017 | | | 42.7 | % | | 42.7 | % | | $ | 2,672 | | | $ | 1,742 | | | 53.3 | % | | 53.3 | % |
| International | | 576 | | | 413 | | | 39.6 | % | | 37.5 | % | | 1,074 | | | 781 | | | 37.6 | % | | 40.1 | % |
| Total | | $ | 2,028 | | | $ | 1,430 | | | 41.8 | % | | 41.2 | % | | $ | 3,746 | | | $ | 2,523 | | | 48.5 | % | | 49.3 | % |
| Humira | United States | | $ | 802 | | | $ | 2,360 | | | (66.0) | % | | (66.0) | % | | $ | 1,546 | | | $ | 4,131 | | | (62.6) | % | | (62.6) | % |
| International | | 378 | | | 454 | | | (16.8) | % | | (17.2) | % | | 755 | | | 953 | | | (20.8) | % | | (18.4) | % |
| Total | | $ | 1,180 | | | $ | 2,814 | | | (58.1) | % | | (58.2) | % | | $ | 2,301 | | | $ | 5,084 | | | (54.7) | % | | (54.3) | % |
| Neuroscience | | | | | | | | | | | | | | | | |
| Vraylar | United States | | $ | 898 | | | $ | 773 | | | 16.2 | % | | 16.2 | % | | $ | 1,661 | | | $ | 1,465 | | | 13.4 | % | | 13.4 | % |
| International | | 2 | | | 1 | | | 72.8 | % | | 76.8 | % | | 4 | | | 3 | | | 41.8 | % | | 47.4 | % |
| Total | | $ | 900 | | | $ | 774 | | | 16.3 | % | | 16.3 | % | | $ | 1,665 | | | $ | 1,468 | | | 13.5 | % | | 13.5 | % |
| Botox Therapeutic | United States | | $ | 775 | | | $ | 669 | | | 15.9 | % | | 15.9 | % | | $ | 1,498 | | | $ | 1,280 | | | 17.0 | % | | 17.0 | % |
| International | | 153 | | | 145 | | | 5.7 | % | | 6.0 | % | | 296 | | | 282 | | | 5.2 | % | | 8.6 | % |
| Total | | $ | 928 | | | $ | 814 | | | 14.1 | % | | 14.2 | % | | $ | 1,794 | | | $ | 1,562 | | | 14.9 | % | | 15.5 | % |
| Ubrelvy | United States | | $ | 330 | | | $ | 227 | | | 46.5 | % | | 46.5 | % | | $ | 563 | | | $ | 424 | | | 33.0 | % | | 33.0 | % |
| International | | 8 | | | 4 | | | 73.9 | % | | 76.7 | % | | 15 | | | 10 | | | 46.7 | % | | 51.2 | % |
| Total | | $ | 338 | | | $ | 231 | | | 47.1 | % | | 47.2 | % | | $ | 578 | | | $ | 434 | | | 33.3 | % | | 33.4 | % |
| Qulipta | United States | | $ | 237 | | | $ | 146 | | | 62.8 | % | | 62.8 | % | | $ | 409 | | | $ | 274 | | | 49.5 | % | | 49.5 | % |
| International | | 30 | | | 4 | | | >100.0 % | | >100.0 % | | 51 | | | 7 | | | >100.0 % | | >100.0 % |
| Total | | $ | 267 | | | $ | 150 | | | 77.5 | % | | 76.9 | % | | $ | 460 | | | $ | 281 | | | 63.6 | % | | 63.6 | % |
| Vyalev | United States | | $ | 22 | | | $ | — | | | n/m | | n/m | | $ | 28 | | | $ | — | | | n/m | | n/m |
| International | | 76 | | | 18 | | | >100.0 % | | >100.0 % | | 133 | | | 27 | | | >100.0 % | | >100.0 % |
| Total | | $ | 98 | | | $ | 18 | | | >100.0 % | | >100.0 % | | $ | 161 | | | $ | 27 | | | >100.0 % | | >100.0 % |
| Duodopa | United States | | $ | 20 | | | $ | 23 | | | (13.6) | % | | (13.6) | % | | $ | 40 | | | $ | 48 | | | (16.6) | % | | (16.6) | % |
| International | | 77 | | | 90 | | | (13.7) | % | | (16.3) | % | | 153 | | | 180 | | | (14.9) | % | | (14.0) | % |
| Total | | $ | 97 | | | $ | 113 | | | (13.7) | % | | (15.7) | % | | $ | 193 | | | $ | 228 | | | (15.2) | % | | (14.5) | % |
| Other Neuroscience | United States | | $ | 51 | | | $ | 57 | | | (11.4) | % | | (11.4) | % | | $ | 106 | | | $ | 118 | | | (10.4) | % | | (10.4) | % |
| International | | 4 | | | 5 | | | (23.3) | % | | (21.3) | % | | 8 | | | 9 | | | (12.7) | % | | (8.1) | % |
| Total | | $ | 55 | | | $ | 62 | | | (12.3) | % | | (12.2) | % | | $ | 114 | | | $ | 127 | | | (10.5) | % | | (10.2) | % |
| Oncology | | | | | | | | | | | | | | | | |
| Imbruvica | United States | | $ | 543 | | | $ | 595 | | | (8.9) | % | | (8.9) | % | | $ | 1,072 | | | $ | 1,205 | | | (11.1) | % | | (11.1) | % |
| Collaboration revenues | | 211 | | | 238 | | | (11.2) | % | | (11.2) | % | | 420 | | | 466 | | | (9.7) | % | | (9.7) | % |
| Total | | $ | 754 | | | $ | 833 | | | (9.5) | % | | (9.5) | % | | $ | 1,492 | | | $ | 1,671 | | | (10.7) | % | | (10.7) | % |
| Venclexta | United States | | $ | 321 | | | $ | 300 | | | 7.4 | % | | 7.4 | % | | $ | 633 | | | $ | 581 | | | 9.1 | % | | 9.1 | % |
| International | | 370 | | | 337 | | | 9.5 | % | | 9.1 | % | | 723 | | | 670 | | | 7.8 | % | | 11.3 | % |
| Total | | $ | 691 | | | $ | 637 | | | 8.5 | % | | 8.3 | % | | $ | 1,356 | | | $ | 1,251 | | | 8.4 | % | | 10.3 | % |
Elahere | United States | | $ | 138 | | | $ | 128 | | | 8.0 | % | | 8.0 | % | | $ | 303 | | | $ | 192 | | | 57.5 | % | | 57.5 | % |
| International | | 21 | | | — | | | n/m | | n/m | | 35 | | | — | | | n/m | | n/m |
| Total | | $ | 159 | | | $ | 128 | | | 24.2 | % | | 23.7 | % | | $ | 338 | | | $ | 192 | | | 75.5 | % | | 75.5 | % |
| Epkinly | Collaboration revenues | | $ | 49 | | | $ | 29 | | | 70.5 | % | | 70.5 | % | | $ | 85 | | | $ | 51 | | | 66.8 | % | | 66.8 | % |
| International | | 21 | | | 7 | | | >100.0 % | | >100.0 % | | 36 | | | 12 | | | >100.0 % | | >100.0 % |
| Total | | $ | 70 | | | $ | 36 | | | 93.9 | % | | 92.3 | % | | $ | 121 | | | $ | 63 | | | 92.1 | % | | 93.3 | % |
| Other Oncology | United States | | $ | 2 | | | $ | — | | | n/m | | n/m | | $ | 2 | | | $ | — | | | n/m | | n/m |
| Aesthetics | | | | | | | | | | | | | | | | |
| Botox Cosmetic | United States | | $ | 410 | | | $ | 450 | | | (8.7) | % | | (8.7) | % | | $ | 705 | | | $ | 839 | | | (15.9) | % | | (15.9) | % |
| International | | 282 | | | 279 | | | 0.9 | % | | 1.2 | % | | 543 | | | 523 | | | 3.7 | % | | 5.8 | % |
| Total | | $ | 692 | | | $ | 729 | | | (5.0) | % | | (4.9) | % | | $ | 1,248 | | | $ | 1,362 | | | (8.4) | % | | (7.6) | % |
| | | | | |
2025 Form 10-Q | | 31 |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | Three months ended
June 30, | | Percent change | | Six months ended
June 30, | | Percent change |
| | | | At actual
currency rates | | At constant
currency rates | | | At actual
currency rates | | At constant
currency rates |
(dollars in millions) | | 2025 | | 2024 | | | 2025 | | 2024 | |
| Juvederm Collection | United States | | $ | 105 | | | $ | 138 | | | (23.6) | % | | (23.6) | % | | $ | 180 | | | $ | 244 | | | (25.9) | % | | (25.9) | % |
| International | | 155 | | | 205 | | | (24.4) | % | | (24.4) | % | | 311 | | | 396 | | | (21.5) | % | | (19.8) | % |
| Total | | $ | 260 | | | $ | 343 | | | (24.0) | % | | (24.0) | % | | $ | 491 | | | $ | 640 | | | (23.2) | % | | (22.2) | % |
| Other Aesthetics | United States | | $ | 282 | | | $ | 275 | | | 1.6 | % | | 1.6 | % | | $ | 552 | | | $ | 556 | | | (1.0) | % | | (1.0) | % |
| International | | 45 | | | 43 | | | 5.8 | % | | 6.4 | % | | 90 | | | 81 | | | 11.7 | % | | 14.5 | % |
| Total | | $ | 327 | | | $ | 318 | | | 2.2 | % | | 2.3 | % | | $ | 642 | | | $ | 637 | | | 0.6 | % | | 0.9 | % |
| Eye Care | | | | | | | | | | | | | | | | |
| Ozurdex | United States | | $ | 30 | | | $ | 35 | | | (12.6) | % | | (12.6) | % | | $ | 60 | | | $ | 69 | | | (12.4) | % | | (12.4) | % |
| International | | 95 | | | 89 | | | 5.8 | % | | 4.4 | % | | 188 | | | 186 | | | 0.8 | % | | 2.7 | % |
| Total | | $ | 125 | | | $ | 124 | | | 0.6 | % | | (0.4) | % | | $ | 248 | | | $ | 255 | | | (2.8) | % | | (1.4) | % |
| Lumigan/Ganfort | United States | | $ | 52 | | | $ | 42 | | | 19.9 | % | | 19.9 | % | | $ | 100 | | | $ | 71 | | | 39.4 | % | | 39.4 | % |
| International | | 51 | | | 61 | | | (15.4) | % | | (15.2) | % | | 109 | | | 123 | | | (11.0) | % | | (7.7) | % |
| Total | | $ | 103 | | | $ | 103 | | | (0.8) | % | | (0.7) | % | | $ | 209 | | | $ | 194 | | | 7.5 | % | | 9.6 | % |
| Alphagan/Combigan | United States | | $ | — | | | $ | 13 | | | (91.6) | % | | (91.6) | % | | $ | 26 | | | $ | 28 | | | (3.6) | % | | (3.6) | % |
| International | | 36 | | | 36 | | | (3.1) | % | | (0.2) | % | | 70 | | | 80 | | | (13.1) | % | | (8.5) | % |
| Total | | $ | 36 | | | $ | 49 | | | (25.6) | % | | (23.5) | % | | $ | 96 | | | $ | 108 | | | (10.6) | % | | (7.2) | % |
| Other Eye Care | United States | | $ | 144 | | | $ | 149 | | | (4.3) | % | | (4.3) | % | | $ | 261 | | | $ | 298 | | | (12.8) | % | | (12.8) | % |
| International | | 106 | | | 108 | | | (1.7) | % | | 0.9 | % | | 206 | | | 216 | | | (4.4) | % | | 0.3 | % |
| Total | | $ | 250 | | | $ | 257 | | | (3.2) | % | | (2.1) | % | | $ | 467 | | | $ | 514 | | | (9.3) | % | | (7.3) | % |
| Other Key Products | | | | | | | | | | | | | | | | |
| Mavyret | United States | | $ | 184 | | | $ | 167 | | | 9.7 | % | | 9.7 | % | | $ | 326 | | | $ | 311 | | | 4.9 | % | | 4.9 | % |
| International | | 191 | | | 202 | | | (5.1) | % | | (6.5) | % | | 355 | | | 407 | | | (12.8) | % | | (11.2) | % |
| Total | | $ | 375 | | | $ | 369 | | | 1.6 | % | | 0.8 | % | | $ | 681 | | | $ | 718 | | | (5.1) | % | | (4.2) | % |
| Creon | United States | | $ | 404 | | | $ | 372 | | | 8.4 | % | | 8.4 | % | | $ | 759 | | | $ | 657 | | | 15.4 | % | | 15.4 | % |
| Linzess/Constella | United States | | $ | 247 | | | $ | 211 | | | 17.4 | % | | 17.4 | % | | $ | 386 | | | $ | 468 | | | (17.4) | % | | (17.4) | % |
| International | | 11 | | | 10 | | | 10.8 | % | | 10.3 | % | | 20 | | | 19 | | | 7.0 | % | | 9.7 | % |
| Total | | $ | 258 | | | $ | 221 | | | 17.1 | % | | 17.1 | % | | $ | 406 | | | $ | 487 | | | (16.5) | % | | (16.4) | % |
| All other | | | $ | 603 | | | $ | 810 | | | (25.4) | % | | (24.8) | % | | $ | 1,350 | | | $ | 1,554 | | | (13.1) | % | | (12.5) | % |
| Total net revenues | | $ | 15,423 | | | $ | 14,462 | | | 6.6 | % | | 6.5 | % | | $ | 28,766 | | | $ | 26,772 | | | 7.4 | % | | 8.0 | % |
n/m – Not meaningful
The following discussion and analysis of AbbVie’s net revenues by product is presented on a constant currency basis.
Net revenues for Skyrizi increased 62% for the three months and 66% for the six months ended June 30, 2025 primarily driven by continued strong market share uptake as well as market growth across all indications.
Net revenues for Rinvoq increased 41% for the three months and 49% for the six months ended June 30, 2025 primarily driven by continued strong market share uptake as well as market growth across all indications.
Net revenues for Humira decreased 58% for the three months and 54% for the six months ended June 30, 2025 primarily driven by continued impact of direct biosimilar competition following the loss of exclusivity.
Net revenues for Vraylar increased 16% for the three months and 14% for the six months ended June 30, 2025 primarily driven by continued market share uptake as well as market growth.
Net revenues for Botox Therapeutic increased 14% for the three months and 16% for the six months ended June 30, 2025 primarily driven by continued market share uptake as well as market growth.
Net revenues for Ubrelvy increased 47% for the three months and 33% for the six months ended June 30, 2025 primarily driven by continued market share uptake as well as favorable pricing.
Net revenues for Qulipta increased 77% for the three months and 64% for the six months ended June 30, 2025 primarily driven by continued strong market share uptake.
Net revenues for Imbruvica represent product revenues in the United States and collaboration revenues outside of the United States related to AbbVie’s 50% share of Imbruvica profit. AbbVie's global Imbruvica revenues decreased 10% for the three months and 11%
| | | | | |
2025 Form 10-Q | | 32 |
for the six months ended June 30, 2025 primarily driven by decreased demand and unfavorable pricing in the United States as well as decreased collaboration revenues.
Net revenues for Venclexta increased 8% for the three months and 10% for the six months ended June 30, 2025 primarily driven by continued market share uptake as well as market growth partially offset by unfavorable pricing.
Net revenues for Elahere increased 24% for the three months and 76% for the six months ended June 30, 2025 primarily driven by increased demand. Net revenues for the six months ended June 30, 2025 were also favorably impacted by a full period of Elahere results in 2025 compared to the prior year.
Net revenues for Botox Cosmetic decreased 5% for the three months and 8% for the six months ended June 30, 2025. In the United States, Botox Cosmetic net revenues decreased 9% for the three months and 16% for the six months ended June 30, 2025 primarily driven by lower market share and decreased consumer demand. Net revenues for the six months ended June 30, 2025 were also impacted by unfavorable pricing due to consumer loyalty program changes in the United States. Internationally, Botox Cosmetic net revenues increased 1% for the three months and 6% for the six months ended June 30, 2025 primarily driven by increased consumer demand across certain international markets.
Net revenues for Juvederm Collection decreased 24% for the three months and 22% for the six months ended June 30, 2025 primarily driven by decreased global consumer demand.
Gross Margin | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | Three months ended
June 30, | | Six months ended
June 30, |
| (dollars in millions) | | 2025 | | 2024 | | % change | | 2025 | | 2024 | | % change |
| Gross margin | | $ | 11,077 | | $ | 10,260 | | 8 | % | | $ | 20,418 | | $ | 18,476 | | 11 | % |
| as a % of net revenues | | 72 | % | | 71 | % | | | | 71 | % | | 69 | % | | |
Gross margin as a percentage of net revenues increased for the three and six months ended June 30, 2025 compared to the prior year primarily due to increased leverage from net revenues growth, lower amortization of intangibles and the favorable impact of acquisition and integration costs incurred during the six months ended June 30, 2024 in connection with the ImmunoGen acquisition partially offset by unfavorable changes in product mix.
Selling, General and Administrative | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | Three months ended
June 30, | | Six months ended
June 30, |
| (dollars in millions) | | 2025 | | 2024 | | % change | | 2025 | | 2024 | | % change |
| Selling, general and administrative | | $ | 3,253 | | $ | 3,377 | | (4) | % | | $ | 6,546 | | $ | 6,692 | | (2) | % |
| as a % of net revenues | | 21 | % | | 23 | % | | | | 23 | % | | 25 | % | | |
Selling, general and administrative (SG&A) expenses as a percentage of net revenues decreased for the three and six months ended June 30, 2025 compared to the prior year. SG&A expense as a percentage of net revenues for the three and six months ended June 30, 2025 was favorably impacted by leverage from revenue growth partially offset by increased restructuring charges. SG&A expense for the six months ended June 30, 2025 was also favorably impacted by acquisition and integration costs incurred during the six months ended June 30, 2024 in connection with the ImmunoGen acquisition.
Research and Development | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | Three months ended
June 30, | | Six months ended
June 30, |
| (dollars in millions) | | 2025 | | 2024 | | % change | | 2025 | | 2024 | | % change |
| Research and development | | $ | 2,131 | | | $ | 1,948 | | | 9 | % | | $ | 4,198 | | $ | 3,887 | | 8 | % |
| as a % of net revenues | | 14 | % | | 13 | % | | | | 15 | % | | 15 | % | | |
Research and development (R&D) expenses as a percentage of net revenues increased for the three months and were flat for the six months ended June 30, 2025 compared to the prior year. R&D expense percentage for the three and six months ended June 30, 2025 was unfavorably impacted by increased funding to support all stages of the company’s pipeline assets. R&D expense percentage for the six months ended June 30, 2025 was also favorably impacted by acquisition and integration costs incurred during the six months ended June 30, 2024 in connection with the ImmunoGen acquisition.
| | | | | |
2025 Form 10-Q | | 33 |
Acquired IPR&D and Milestones
| | | | | | | | | | | | | | | | | | | | | | | | | | |
| | Three months ended
June 30, | | Six months ended
June 30, |
| (dollars in millions) | | 2025 | | 2024 | | 2025 | | 2024 |
| Upfront charges | | $ | 705 | | | $ | 927 | | | $ | 951 | | | $ | 1,006 | |
| Development milestones | | 118 | | | 10 | | | 120 | | | 95 | |
| Acquired IPR&D and milestones | | $ | 823 | | | $ | 937 | | | $ | 1,071 | | | $ | 1,101 | |
Acquired IPR&D and milestones expense for the three and six months ended June 30, 2025 included charges related to the upfront payments of $350 million to Gubra A/S for an exclusive global license to develop and commercialize GUB014295 (ABBV-295) and $335 million to ADARx Pharmaceuticals, Inc. for exclusive options to global license rights to develop and commercialize ADARx’s small interfering RNA (siRNA) therapeutics. Acquired IPR&D and milestones expense for the three and six months ended June 30, 2024 included a charge related to the upfront payment of $250 million to acquire Celsius Therapeutics. See Note 4 to the condensed consolidated financial statements for additional information.
Other Non-Operating Expenses (Income)
| | | | | | | | | | | | | | | | | | | | | | | | | | |
| | Three months ended
June 30, | | Six months ended
June 30, |
| (in millions) | | 2025 | | 2024 | | 2025 | | 2024 |
| Interest expense | | $ | 740 | | | $ | 726 | | | $ | 1,440 | | | $ | 1,386 | |
| Interest income | | (62) | | | (220) | | | (135) | | | (427) | |
| Interest expense, net | | $ | 678 | | | $ | 506 | | | $ | 1,305 | | | $ | 959 | |
| | | | | | | | |
| Net foreign exchange loss | | $ | 23 | | | $ | 1 | | | $ | 27 | | | $ | 5 | |
| Other expense, net | | 2,639 | | | 1,345 | | | 4,080 | | | 1,931 | |
Interest expense increased for the three and six months ended June 30, 2025 compared to the prior year primarily due to a higher average debt balance.
Interest income decreased for the three and six months ended June 30, 2025 compared to the prior year primarily due to a lower average cash and equivalents balance.
Other expense, net included charges related to changes in fair value of contingent consideration liabilities of $2.8 billion for the three months and $4.3 billion for the six months ended June 30, 2025 and $1.5 billion for the three months and $2.1 billion for the six months ended June 30, 2024. The fair value of contingent consideration liabilities is impacted by the passage of time and multiple other inputs, including the probability of success of achieving regulatory milestones, discount rates, the estimated amount of future sales of the acquired products and other market-based factors. For the three and six months ended June 30, 2025, the change in fair value reflected higher estimated Skyrizi sales, the passage of time and lower discount rates. For the three and six months ended June 30, 2024, the change in fair value reflected higher estimated Skyrizi sales and the passage of time, partially offset by higher discount rates.
Income Tax Expense
The effective tax rate was 39% for the three months and 31% for the six months ended June 30, 2025 compared to 36% for the three months and 30% for the six months ended June 30, 2024. The effective tax rate in each period differed from the U.S. statutory tax rate of 21% principally due to the impact of foreign operations which reflects the impact of lower income tax rates in locations outside the United States, changes in fair value of contingent consideration and business development activities. The increase in the effective tax rate for the three and six months ended June 30, 2025 over the prior year was primarily due to changes in fair value of contingent consideration offset by changes in jurisdictional mix of earnings and business development activities.
| | | | | |
2025 Form 10-Q | | 34 |
FINANCIAL POSITION, LIQUIDITY AND CAPITAL RESOURCES | | | | | | | | | | | |
| Six months ended
June 30, |
| (in millions) | 2025 | | 2024 |
| Cash flows provided by (used in): | | | |
| Operating activities | $ | 6,788 | | | $ | 6,311 | |
| Investing activities | (1,916) | | | (10,690) | |
| Financing activities | (3,968) | | | 4,722 | |
Operating cash flows for the six months ended June 30, 2025 increased compared to the prior year primarily due to increased results from operations driven by higher net revenues and lower acquisition-related cash expenses partially offset by higher payments related to litigation matters and higher payments of contingent consideration liabilities.
Investing cash flows for the six months ended June 30, 2025 included payments made for other acquisitions and investments of $1.3 billion and capital expenditures of $504 million. Investing cash flows for the six months ended June 30, 2024 included $9.8 billion cash consideration paid to acquire ImmunoGen offset by cash acquired of $591 million, payments made for other acquisitions and investments of $1.0 billion and capital expenditures of $434 million.
Financing cash flows for the six months ended June 30, 2025 included the issuance of unsecured senior notes totaling $4.0 billion aggregate principal and $2.0 billion under the 364-day term loan credit agreement. Financing cash flows also included the repayment of $3.0 billion aggregate principal of 3.80% senior notes and $3.8 billion aggregate principal of 3.60% senior notes. Financing cash flows for the six months ended June 30, 2024 included the issuance of unsecured senior notes totaling $15.0 billion aggregate principal which were used to finance the acquisitions of ImmunoGen and Cerevel Therapeutics. Additionally, financing cash flows included the issuance and repayment of $5.0 billion under the term loan credit agreement and repayments of €1.5 billion aggregate principal amount of 1.38% senior euro notes, €700 million aggregate principal amount of 1.25% senior euro notes, $1.0 billion aggregate principal amount of 3.85% senior notes and $99 million of secured term notes assumed from ImmunoGen in conjunction with the acquisition.
Financing cash flows also included cash dividend payments of $5.8 billion for the six months ended June 30, 2025 and $5.5 billion for the six months ended June 30, 2024. The increase in cash dividend payments was primarily driven by the increase in the quarterly dividend rate.
On June 20, 2025, the company announced that its board of directors declared a quarterly cash dividend of $1.64 per share for stockholders of record at the close of business on July 15, 2025, payable on August 15, 2025. The timing, declaration, amount of and payment of any dividends by AbbVie in the future is within the discretion of its board of directors and will depend upon many factors, including AbbVie’s financial condition, earnings, capital requirements of its operating subsidiaries, covenants associated with certain of AbbVie’s debt service obligations, legal requirements, regulatory constraints, industry practice, ability to access capital markets and other factors deemed relevant by its board of directors.
The company's stock repurchase authorization permits purchases of AbbVie shares from time to time in open-market or private transactions at management's discretion. The program has no time limit and can be discontinued at any time. On February 16, 2023, AbbVie’s board of directors authorized a $5.0 billion increase to the existing stock repurchase authorization. AbbVie repurchased 3 million shares for $606 million during the six months ended June 30, 2025 and 5 million shares for $959 million during the six months ended June 30, 2024.
During the six months ended June 30, 2025 and 2024, the company issued and redeemed commercial paper. The balance of commercial paper borrowings outstanding was $3.6 billion as of June 30, 2025, of which $2.0 billion had original maturities greater than three months. There were no commercial paper borrowings outstanding as of December 31, 2024. AbbVie may issue additional commercial paper or retire commercial paper to meet liquidity requirements as needed.
Credit Risk
AbbVie monitors economic conditions, the creditworthiness of customers and government regulations and funding, both domestically and abroad. AbbVie regularly communicates with its customers regarding the status of receivable balances, including their payment plans and obtains positive confirmation of the validity of the receivables. AbbVie establishes an allowance for credit losses equal to the estimate of future losses over the contractual life of outstanding accounts receivable. AbbVie may also utilize factoring arrangements to mitigate credit risk, although the receivables included in such arrangements have historically not been a significant amount of total outstanding receivables.
| | | | | |
2025 Form 10-Q | | 35 |
Credit Facility, Access to Capital and Credit Ratings
Credit Facility
In January 2025, AbbVie entered into a new $3.0 billion five-year revolving credit facility that matures in January 2030 which is in addition to the existing $5.0 billion five-year revolving credit facility that matures in March 2028. The revolving credit facilities are available to support AbbVie’s commercial paper program and enable the company to borrow funds to meet liquidity requirements on an unsecured basis at variable interest rates and contain various covenants. At June 30, 2025, the company was in compliance with all covenants, and commitment fees under the credit facility were insignificant. No amounts were outstanding under the company's credit facility as of June 30, 2025 and December 31, 2024.
In April 2025, the company entered into a $4.0 billion 364-day term loan credit agreement. In May 2025, the company borrowed $2.0 billion under this term loan credit agreement which was outstanding and included in short-term borrowings on the condensed consolidated balance sheet as of June 30, 2025.
In December 2023, in connection with the acquisitions of ImmunoGen and Cerevel Therapeutics, AbbVie entered into a $9.0 billion 364-day bridge credit agreement and $5.0 billion 364-day term loan credit agreement. In February 2024, AbbVie borrowed and repaid $5.0 billion under the term loan credit agreement. Subsequent to the $15.0 billion issuance of senior notes, AbbVie terminated both the bridge and term loan credit agreements in the first quarter of 2024.
Access to Capital
The company intends to fund short-term and long-term financial obligations as they mature through cash on hand, future cash flows from operations or has the ability to issue additional debt. The company’s ability to generate cash flows from operations, issue debt or enter into financing arrangements on acceptable terms could be adversely affected if there is a material decline in the demand for the company’s products or in the solvency of its customers or suppliers, deterioration in the company’s key financial ratios or credit ratings or other material unfavorable changes in business conditions. At the current time, the company believes it has sufficient financial flexibility to issue debt, enter into other financing arrangements and attract long-term capital on acceptable terms to support the company’s growth objectives.
Credit Ratings
There were no changes in the company’s credit ratings during the six months ended June 30, 2025. Unfavorable changes to the ratings may have an adverse impact on future financing arrangements; however, they would not affect the company’s ability to draw on its credit facility and would not result in an acceleration of scheduled maturities of any of the company’s outstanding debt.
CRITICAL ACCOUNTING POLICIES
A summary of the company’s significant accounting policies is included in Note 2, “Summary of Significant Accounting Policies” in AbbVie's Annual Report on Form 10-K for the year ended December 31, 2024. There have been no significant changes in the company’s application of its critical accounting policies during the six months ended June 30, 2025.
FORWARD-LOOKING STATEMENTS
Some statements in this quarterly report on Form 10-Q are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. The words “believe,” “expect,” “anticipate,” “project,” and similar expressions and uses of future or conditional verbs, generally identify forward-looking statements. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied in the forward-looking statements. Such risks and uncertainties include, but are not limited to challenges to intellectual property, competition from other products, difficulties inherent in the research and development process, adverse litigation or government action, changes to laws and regulations applicable to our industry, the impact of global macroeconomic factors, such as economic downturns or uncertainty, international conflict, trade disputes and tariffs, and other uncertainties and risks associated with global business operations. Additional information about the economic, competitive, governmental, technological and other factors that may affect AbbVie’s operations is set forth in Item 1A, “Risk Factors,” in AbbVie’s Annual Report on Form 10-K for the year ended December 31, 2024, which has been filed with the Securities and Exchange Commission. AbbVie notes these factors for investors as permitted by the Private Securities Litigation Reform Act of 1995. AbbVie undertakes no obligation, and specifically declines, to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.
| | | | | |
2025 Form 10-Q | | 36 |
ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK For a discussion of the company's market risk, see Item 7A, "Quantitative and Qualitative Disclosures About Market Risk" in AbbVie's Annual Report on Form 10-K for the year ended December 31, 2024.
ITEM 4. CONTROLS AND PROCEDURES DISCLOSURE CONTROLS AND PROCEDURES
Evaluation of disclosure controls and procedures. The Chief Executive Officer, Robert A. Michael, and the Chief Financial Officer, Scott T. Reents, evaluated the effectiveness of AbbVie's disclosure controls and procedures as of the end of the period covered by this report, and concluded that AbbVie's disclosure controls and procedures were effective to ensure that information AbbVie is required to disclose in the reports that it files or submits with the Securities and Exchange Commission under the Securities Exchange Act of 1934 is recorded, processed, summarized and reported, within the time periods specified in the Securities and Exchange Commission's rules and forms, and to ensure that information required to be disclosed by AbbVie in the reports that it files or submits under the Securities Exchange Act of 1934 is accumulated and communicated to AbbVie's management, including its principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure.
INTERNAL CONTROL OVER FINANCIAL REPORTING
Changes in internal control over financial reporting. There were no changes in AbbVie's internal control over financial reporting (as defined in Rule 13a-15(f) under the Securities Exchange Act of 1934) that have materially affected, or are reasonably likely to materially affect, AbbVie's internal control over financial reporting during the quarter ended June 30, 2025.
Inherent Limitations on Effectiveness of Controls. AbbVie’s management, including its Chief Executive Officer and its Chief Financial Officer, do not expect that AbbVie’s disclosure controls or internal control over financial reporting will prevent or detect all errors and all fraud. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the control system’s objectives will be met. The design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Further, because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud, if any, have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty and that breakdowns can occur because of simple error or mistake. Controls can also be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the controls.
The design of any system of controls is based in part on certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Projections of any evaluation of controls effectiveness to future periods are subject to risks. Over time, controls may become inadequate because of changes in conditions or deterioration in the degree of compliance with policies or procedures.
| | | | | |
2025 Form 10-Q | | 37 |
PART II. OTHER INFORMATION
ITEM 1. LEGAL PROCEEDINGS Information pertaining to legal proceedings is provided in Note 12 to the Condensed Consolidated Financial Statements and is incorporated by reference herein.
ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS
(c) Issuer Purchases of Equity Securities
| | | | | | | | | | | | | | | | | | | | | | | | | | |
| Period | (a) Total
Number of
Shares (or Units)
Purchased | | (b) Average
Price Paid
per Share
(or Unit) | | (c) Total Number
of Shares (or
Units) Purchased
as Part of Publicly
Announced Plans
or Programs | |
(d) Maximum
Number (or
Approximate
Dollar Value) of
Shares (or Units)
that May Yet Be
Purchased Under
the Plans or
Programs | |
| April 1, 2025 - April 30, 2025 | 1,102 | | (1) | $183.12 | (1) | — | | | $2,896,110,760 | |
| May 1, 2025 - May 31, 2025 | 995 | | (1) | $189.46 | (1) | — | | | $2,896,110,760 | |
| June 1, 2025 - June 30, 2025 | 1,081 | | (1) | $190.21 | (1) | — | | | $2,896,110,760 | |
| Total | 3,178 | | (1) | $187.52 | (1) | — | | | $2,896,110,760 | |
1.In addition to AbbVie shares repurchased on the open market under a publicly announced program, these shares also included the shares purchased on the open market for the benefit of participants in the AbbVie Employee Stock Purchase Plan – 1,102 in April; 995 in May; and 1,081 in June.
These shares do not include the shares surrendered to AbbVie to satisfy minimum tax withholding obligations in connection with the vesting or exercise of stock-based awards.
(c) Director and Officer Trading Arrangements
During the three months ended June 30, 2025, no director or officer of the company , modified or a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as each term is defined in Item 408(a) of Regulation S-K.
| | | | | |
2025 Form 10-Q | | 38 |
Exhibits 32.1 and 32.2 are furnished herewith and should not be deemed to be “filed” under the Securities Exchange Act of 1934.
| | | | | | | | | | | |
| Exhibit No. | | Exhibit Description | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| 101 | | The following financial statements and notes from the AbbVie Inc. Quarterly Report on Form 10-Q for the quarter ended June 30, 2025, filed on August 4, 2025, formatted in iXBRL (Inline eXtensible Business Reporting Language): (i) Condensed Consolidated Statements of Earnings; (ii) Condensed Consolidated Statements of Comprehensive Income; (iii) Condensed Consolidated Balance Sheets; (iv) Condensed Consolidated Statements of Equity (Deficit); (v) Condensed Consolidated Statements of Cash Flows; and (vi) the Notes to Condensed Consolidated Financial Statements. | |
| | | |
| 104 | | Cover Page Interactive Data File (the cover page from the AbbVie Inc. Quarterly Report on Form 10-Q formatted as Inline XBRL and contained in Exhibit 101). | |
_______________________________________________________________________________
* Denotes management contract or compensatory plan or arrangement required to be filed as an exhibit hereto.
| | | | | |
2025 Form 10-Q | | 39 |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| | | | | | | | |
| | ABBVIE INC. |
| | |
| | |
| By: | /s/ Scott T. Reents |
| | Scott T. Reents |
| | Executive Vice President, |
| | Chief Financial Officer (Principal Financial Officer) |
Date: August 4, 2025
| | | | | |
2025 Form 10-Q | | 40 |
Similar companies
See also JOHNSON & JOHNSON -
Annual report 2024 (10-K 2024-12-29)
Annual report 2025 (10-Q 2025-06-29)
See also ELI LILLY & Co -
Annual report 2024 (10-K 2024-12-31)
Annual report 2025 (10-Q 2025-06-30)
See also PFIZER INC -
Annual report 2024 (10-K 2024-12-31)
Annual report 2025 (10-Q 2025-03-30)
See also NOVO NORDISK A S
See also Merck & Co., Inc. -
Annual report 2024 (10-K 2024-12-31)
Annual report 2025 (10-Q 2025-06-30)
Open main menu